← Evidence map

ArticleDiabetes care2015

Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158.

Michael Nauck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158. | Socratic